ArticleTissue engineering and regenerative medicine2026
Comparative Study of Mesenchymal Stem Cell Identity and Chondrogenic Differentiation Capacity of Human Nucleus Pulposus, Adipose and Bone Marrow Tissues Derived Mesenchymal Stem Cells.
Article in Tissue engineering and regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMesenchymal stem cells (MSCs) are multipotent mesoderm-derived cells with high proliferation capacity, self-renewal, paracrine activity, and multilineage differentiation potential. Autologous MSCs from the same patients are particularly valuable for regenerative therapies, including those targeting degenerative intervertebral disc disorder (DIVDD).
methodsIn this study, we directly compared autologous MSC sources obtained from the same patients, thereby reducing biological variability and strengthening translational relevance. We compared MSCs isolated from bone marrow (BM-MSCs), adipose tissue (AD-MSCs), and nucleus pulposus (NP-MSCs) obtained from the same DIVDD patient donor (N = 10 donors). We assessed their morphologies, proliferation abilities, immunophenotype, multilineage differentiation capacity, and chondrogenic differentiation-related gene and protein expression.
resultsAll three MSC populations displayed similar fibroblast-like morphology and consistent immunophenotypic profiles. However, their functional properties differed: AD-MSCs exhibited significantly higher proliferative activity and greater adipogenic differentiation potential (p < 0.01 and p < 0.001), while osteogenic and chondrogenic differentiation capacities were comparable across BM-MSCs, AD-MSCs, and NP-MSCs at both gene and protein levels (SOX9 and COMP).
conclusionThese findings suggest that AD-MSCs offer practical advantages in terms of proliferation capacity and accessibility. However, chondrogenic differentiation capacity was largely comparable across MSC sources. Further mechanistic studies and in vivo validation are required to determine their relative therapeutic efficacy for intervertebral disc regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.